Literature DB >> 15547635

Keep moving: patients with myeloma talk about exercise and fatigue.

Sharon K Coon1, Elizabeth Ann Coleman.   

Abstract

PURPOSE/
OBJECTIVES: To learn about the feelings, beliefs, and experiences of patients with multiple myeloma implementing an exercise program in the context of an aggressive tandem peripheral stem cell transplant protocol. RESEARCH APPROACH: Qualitative naturalistic (constructionist).
SETTING: International referral center for the treatment of multiple myeloma. PARTICIPANTS: Purposive nonprobability sample of 12 men and 9 women with multiple myeloma aged 38-70 enrolled in the exercise arm of a randomized trial of epoetin alfa with or without exercise as an intervention to decrease cancer-related fatigue. METHODOLOGIC APPROACH: Verbatim transcripts of tape-recorded, in-depth interviews analyzed for thematic content using content analysis and constant comparison.
FINDINGS: Themes included (a) belief systems, which encompassed participants' beliefs about exercise and epoetin alfa, philosophy, and self-concept, (b) social context, which included life before cancer, social environment, and social system congruence, and (c) intersection between belief systems and social context, which were participants' experience appraisals. All participants believed that exercise could be helpful and would recommend exercise to other patients with cancer in a similar situation. Most believed that lack of activity contributed to decreased energy. MAIN RESEARCH VARIABLE: Patients' experience of implementing exercise in the context of treatment for multiple myeloma.
CONCLUSIONS: Complex interactions between participants' beliefs and social context and experience appraisal influenced their ability to adhere to an exercise program during aggressive treatment for multiple myeloma.
INTERPRETATION: Through careful assessment, clinicians can capitalize on belief and social systems that support adherence to exercise as an intervention to ameliorate fatigue for patients with cancer who are undergoing prolonged aggressive treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15547635     DOI: 10.1188/04.ONF.1127-1135

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  7 in total

1.  Physical activity participation and barriers for people with multiple myeloma.

Authors:  Melinda Craike; Kaye Hose; Patricia M Livingston
Journal:  Support Care Cancer       Date:  2012-10-02       Impact factor: 3.603

2.  Exercise compliance among patients with multiple myeloma undergoing chemotherapy: a retrospective study.

Authors:  Shirin Shallwani; Mary-Ann Dalzell; Warren Sateren; Suzanne O'Brien
Journal:  Support Care Cancer       Date:  2015-03-06       Impact factor: 3.603

3.  Cancer prevention, aerobic capacity, and physical functioning in survivors related to physical activity: a recent review.

Authors:  Matthew S Wiggins; Emily M Simonavice
Journal:  Cancer Manag Res       Date:  2010-06-09       Impact factor: 3.989

Review 4.  Physical Activity and Quality of Life in Cancer Survivors: A Meta-Synthesis of Qualitative Research.

Authors:  Shaunna Burke; Amanda Wurz; Andrew Bradshaw; Stephanie Saunders; Malcolm A West; Jennifer Brunet
Journal:  Cancers (Basel)       Date:  2017-05-20       Impact factor: 6.639

Review 5.  Psychosocial Determinants of Lifestyle Change after a Cancer Diagnosis: A Systematic Review of the Literature.

Authors:  Meeke Hoedjes; Inge Nijman; Chris Hinnen
Journal:  Cancers (Basel)       Date:  2022-04-16       Impact factor: 6.575

6.  Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study.

Authors:  Melinda J Craike; Kaye Hose; Kerry S Courneya; Simon J Harrison; Patricia M Livingston
Journal:  BMC Cancer       Date:  2013-07-01       Impact factor: 4.430

Review 7.  Multiple myeloma and physical activity: a scoping review.

Authors:  Lee Smith; Orla McCourt; Malgorzata Henrich; Bruce Paton; Kwee Yong; Jane Wardle; Abigail Fisher
Journal:  BMJ Open       Date:  2015-11-27       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.